GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Shiller PE Ratio

Axsome Therapeutics (STU:19X) Shiller PE Ratio : (As of Apr. 25, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Axsome Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Shiller PE Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Axsome Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Axsome Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Axsome Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Shiller PE Ratio falls into.


;
;

Axsome Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Axsome Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Axsome Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.471/133.1571*133.1571
=-1.471

Current CPI (Dec. 2024) = 133.1571.

Axsome Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.155 99.621 -0.207
201506 -0.149 100.684 -0.197
201509 -0.230 100.392 -0.305
201512 -0.110 99.792 -0.147
201603 -0.278 100.470 -0.368
201606 -0.320 101.688 -0.419
201609 -0.339 101.861 -0.443
201612 -0.360 101.863 -0.471
201703 -0.383 102.862 -0.496
201706 -0.267 103.349 -0.344
201709 -0.227 104.136 -0.290
201712 -0.262 104.011 -0.335
201803 -0.154 105.290 -0.195
201806 -0.274 106.317 -0.343
201809 -0.266 106.507 -0.333
201812 -0.281 105.998 -0.353
201903 -0.283 107.251 -0.351
201906 -0.363 108.070 -0.447
201909 -0.508 108.329 -0.624
201912 -0.639 108.420 -0.785
202003 -0.796 108.902 -0.973
202006 -0.435 108.767 -0.533
202009 -0.518 109.815 -0.628
202012 -0.641 109.897 -0.777
202103 -0.655 111.754 -0.780
202106 -0.714 114.631 -0.829
202109 -0.791 115.734 -0.910
202112 -0.797 117.630 -0.902
202203 -0.935 121.301 -1.026
202206 -1.003 125.017 -1.068
202209 -1.081 125.227 -1.149
202212 -1.331 125.222 -1.415
202303 -0.243 127.348 -0.254
202306 -1.421 128.729 -1.470
202309 -1.237 129.860 -1.268
202312 -1.907 129.419 -1.962
202403 -1.325 131.776 -1.339
202406 -1.551 132.554 -1.558
202409 -1.207 133.029 -1.208
202412 -1.471 133.157 -1.471

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (STU:19X) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Axsome Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics Business Description

Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines